Selected Publications

Jadlowsky JK, Hexner EO, Marshall A, Grupp SA, Frey NV, Riley JL, Veloso E, McConville H, Rogal W, Czuczman C, Hwang WT, Li Y, Leskowitz RM, Farrelly O, Karar J, Christensen S, Barber-Rotenberg J, Gaymon A, Aronson N, Bernstein W, Melenhorst JJ, Roche AM, Everett JK, Zolnoski SA, McFarland AG, Reddy S, Petrichenko A, Cook EJ, Lee C, Gonzalez VE, Alexander K, Kulikovskaya I, Ramírez-Fernández Á, Minehart JC, Ruella M, Gill SI, Schuster SJ, Cohen AD, Garfall AL, Shah PD, Porter DL, Maude SL, Levine BL, Siegel DL, Chew A, McKenna S, Lledo L, Davis MM, Plesa G, Herbst F, Stadtmauer EA, Tebas P, DiNofia A, Haas A, Haas NB, Myers R, O'Rourke DM, Svoboda J, Tanyi JL, Aplenc R, Jacobson JM, Ko AH, Cohen RB, June CH, Bushman FD, Fraietta JA.: Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies. Nat Med 31(4): 1134-1144, Apr 2025.

Till JE, Seewald NJ, Yazdani Z, Wang Z, Ballinger D, Samberg H, Dandu S, Macia C, Yin M, Abdalla A, Prior T, Shah SS, Patel T, McCoy E, Mansour M, Wills CA, Bochenek V, Serrano J, Snuderl M, Phillips RE, O'Rourke DM, Amankulor NM, Nabavizadeh A, Desai AS, Gollomp K, Binder ZA, Zhou W, Bagley SJ, Carpenter EL: Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with Glioblastoma. Clin Cancer Res 31(7): 1292-1304, Apr 2025.

Fathi Kazerooni A, Akbari H, Hu X, Bommineni V, Grigoriadis D, Toorens E, Sako C, Mamourian E, Ballinger D, Sussman R, Singh A, Verginadis II, Dahmane N, Koumenis C, Binder ZA, Bagley SJ, Mohan S, Hatzigeorgiou A, O'Rourke DM, Ganguly T, De S, Bakas S, Nasrallah MP, Davatzikos C: The radiogenomic and spatiogenomic landscapes of glioblastoma and their relationship to oncogenic drivers. Commun Med (Lond) 5(1): 55, Mar 2025.

Logun M, Wang X, Sun YY, Bagley S, Li N, Desai A, Zhang DY, Nasrallah M, Pai EL, Oner BS, Plesa G, Siegel D, Binder ZA, Ming GL, Song H, O’Rourke DM: Patient-derived glioblastoma organoids as real-time avatars for assessing responses to clinical CAR-T cell therapy. Cell Stem Cell 32(2): 181-90, Feb 2025.

Sun Y, Wang X, Zhang DY, Zhang Z, Bhattarai JP, Wang Y, Park KH, Dong W, Hung YF, Yang Q, Zhang F, Rajamani K, Mu S, Kennedy BC, Hong Y, Galanaugh J, Sambangi A, Kim SH, Wheeler G, Gonçalves T, Wang Q, Geschwind DH, Kawaguchi R, Viaene AN, Helbig I, Kessler SK, Hoke A, Wang H, Xu F, Binder ZA, Isaac Chen H, Pai EL, Stone S, Nasrallah MP, Christian KM, Fuccillo M, Toni N, Wu Z, Cheng HJ, O'Rourke DM, Ma M, Ming GL, Song H.: Brain-wide neuronal circuit connectome of human glioblastoma. Nature Jan 2025.

Akbari H, Bakas S, Sako C, Fathi Kazerooni A, Villanueva-Meyer J, Garcia JA, Mamourian E, Liu F, Cao Q, Shinohara RT, Baid U, Getka A, Pati S, Singh A, Calabrese E, Chang S, Rudie J, Sotiras A, LaMontagne P, Marcus DS, Milchenko M, Nazeri A, Balana C, Capellades J, Puig J, Badve C, Barnholtz-Sloan JS, Sloan AE, Vadmal V, Waite K, Ak M, Colen RR, Park YW, Ahn SS, Chang JH, Choi YS, Lee SK, Alexander GS, Ali AS, Dicker AP, Flanders AE, Liem S, Lombardo J, Shi W, Shukla G, Griffith B, Poisson LM, Rogers LR, Kotrotsou A, Booth TC, Jain R, Lee M, Mahajan A, Chakravarti A, Palmer JD, DiCostanzo D, Fathallah-Shaykh H, Cepeda S, Santonocito OS, Di Stefano AL, Wiestler B, Melhem ER, Woodworth GF, Tiwari P, Valdes P, Matsumoto Y, Otani Y, Imoto R, Aboian M, Koizumi S, Kurozumi K, Kawakatsu T, Alexander K, Satgunaseelan L, Rulseh AM, Bagley SJ, Bilello M, Binder ZA, Brem S, Desai AS, Lustig RA, Maloney E, Prior T, Amankulor N, Nasrallah MLP, O'Rourke DM, Mohan S, Davatzikos C; ReSPOND consortium.: Machine Learning-based Prognostic Subgrouping of Glioblastoma: A Multi-center Study. Neuro Oncol Dec 2024.

Li N, Rodriguez JL, Yin Y, Logun MT, Zhang L, Yu S, Hicks KA, Zhang JV, Zhang L, Xie C, Wang J, Wang T, Xu J, Fraietta JA, Binder ZA, Lin Z, O'Rourke DM: Armored bicistronic CAR T cells with dominant-negative TGF-β receptor II to overcome resistance in glioblastoma. Mol Ther 32(10): 3522-3538, Oct 2024.

Gongala S, Garcia JA, Korakavi N, Patil N, Akbari H, Sloan A, Barnholtz-Sloan JS, Sun J, Griffith B, Poisson LM, Booth TC, Jain R, Mohan S, Nasralla MP, Bakas S, Tippareddy C, Puig J, Palmer JD, Shi W, Colen RR, Sotiras A, Ahn SS, Park YW, Davatzikos C, Badve C; ReSPOND Consortium: Sex-Specific Differences in Patients with IDH1-Wild-Type Grade 4 Glioma in the ReSPOND Consortium. AJNR Am J Neuroradiol 45(9), Sept 2024.

Liu J, Cao S, Imbach KJ, Gritsenko MA, Lih TM, Kyle JE, Yaron-Barir TM, Binder ZA, Li Y, Strunilin I, Wang YT, Tsai CF, Ma W, Chen L, Clark NM, Shinkle A, Naser Al Deen N, Caravan W, Houston A, Simin FA, Wyczalkowski MA, Wang LB, Storrs E, Chen S, Illindala R, Li YD, Jayasinghe RG, Rykunov D, Cottingham SL, Chu RK, Weitz KK, Moore RJ, Sagendorf T, Petyuk VA, Nestor M, Bramer LM, Stratton KG, Schepmoes AA, Couvillion SP, Eder J, Kim YM, Gao Y, Fillmore TL, Zhao R, Monroe ME, Southard-Smith AN, Li YE, Jui-Hsien Lu R, Johnson JL, Wiznerowicz M, Hostetter G, Newton CJ, Ketchum KA, Thangudu RR, Barnholtz-Sloan JS, Wang P, Fenyö D, An E, Thiagarajan M, Robles AI, Mani DR, Smith RD, Porta-Pardo E, Cantley LC, Iavarone A, Chen F, Mesri M, Nasrallah MP, Zhang H, Resnick AC, Chheda MG, Rodland KD, Liu T, Ding L; Philadelphia Coalition for a Cure; Clinical Proteomic Tumor Analysis Consortium: Multi-scale signaling and tumor evolution in high-grade gliomas. Cancer Cell 42(7): 1217-38, July 2024.

Bagley SJ, Logun M, Fraietta JA, Wang X, Desai AS, Bagley LJ, Nabavizadeh A, Jarocha D, Martins R, Maloney E, Lledo L, Stein C, Marshall A, Leskowitz R, Jadlowsky JK, Christensen S, Oner BS, Plesa G, Brennan A, Gonzalez V, Chen F, Sun Y, Gladney W, Barrett D, Nasrallah MP, Hwang WT, Ming GL, Song H, Siegel DL, June CH, Hexner EO, Binder ZA, O'Rourke DM: Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results. Nat Med. 30(5): 1320-1329, May 2024.